Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 30 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Bowel functions and bile Acids in patients with irritable bowel syndrome

May's issue of Clinical Gastroenterology & Hepatology investigates bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.

News image

There is an unclear relationship among bowel symptoms, excretion of unconjugated fecal bile acid, and colonic transit in irritable bowel syndrome.

Dr Andrea Shin and colleagues measured total and main individual unconjugated fecal bile acid in fecal samples of patients with irritable bowel syndrome (IBS), and assessed relationships among stool frequency or consistency, fecal unconjugated fecal bile acid, and colonic transit.

The team examined 30 healthy volunteers, 31 subjects with irritable bowel syndrome with diarrhea, and 30 with irritable bowel syndrome with constipation.

The patients were placed on 4-day diets containing 100 g fat.

The researchers measured stool characteristics, total fecal unconjugated fecal bile acid and fat levels, and overall colonic transit. 

The team assessed univariate associations of total and individual levels of fecal unconjugated fecal bile acid with phenotype using the Kruskal-Wallis test, and associations between endpoints were assessed using Spearman correlations.

The research team assessed relationships between stool, colonic transit, and fecal total and secretory unconjugated fecal bile acid.

Total fecal unconjugated fecal bile acid was associated with phenotype
Clinical Gastroenterology and Hepatology

There was a significant association between total fecal unconjugated fecal bile acid and phenotype.

The team found that the association was greater for irritable bowel syndrome-D than irritable bowel syndrome-C, compared with controls.

The doctors noted that fecal levels of primary unconjugated fecal bile acid were higher in subjects with irritable bowel syndrome-D, compared with controls.

Levels of fecal secretory unconjugated fecal bile acid were lower in subjects with irritable bowel syndrome-C compared with controls, whereas levels of the nonsecretory unconjugated fecal bile acid, lithocholic acid, were higher.

The researchers found significant univariate associations between stool number and form and total fecal unconjugated fecal bile acid, fecal fat, and colonic transit at 24 and 48 hours after eating.

In the regression models, the relative contribution of colonic transit was consistently greater, and largely independent of the contribution of bile acids.

Dr Shin's team commented, "Measurements of individual unconjugated fecal bile acids identify changes associated with stool characteristics in patients with irritable bowel syndrome."

"These effects are independent of the effects of colonic transit."

Clin Gastroenterol Hepatol 2013
13 May 2013

Go to top of page Email this page Email this page to a colleague

 30 September 2016 
Gluten breakdown and immunogenicity in celiac disease
 30 September 2016 
Noninvasive detection of NASH
 30 September 2016 
CEA levels to detect recurrent colorectal cancer
 29 September 2016 
Biologic therapies in IBD
 29 September 2016 
Predicting the prognosis of gastric cancer
 29 September 2016 
Predicting symptomatic outcomes in GERD
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us